ArticleIndian dermatology online journal2026
Phototherapy with Topical Minoxidil in Vitiligo: A Randomized Control Trial.
Article in Indian dermatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhototherapy is the most commonly used treatment for vitiligo, with initial pigment appearing at the perifollicular site, eventually coalescing into uniform pigmentation due to melanocyte migration from hair follicles. Melanocyte activity is higher during the anagen phase of the hair cycle, which is prolonged by minoxidil.
aimTo assess if topical minoxidil enhances the rate of pigmentation during phototherapy for the treatment of vitiligo. PATIENTS AND
methodsIn this double-blinded, randomized control study, the efficacy of minoxidil in inducing repigmentation was compared with the vehicle used as a placebo. Thirty vitiligo patients with a minimum of 2 patches were included and randomized into 2 groups and treated with phototherapy. Minoxidil 5% solution was randomly applied on one patch and vehicle on the other patch. The vitiligo area severity index (VASI) score of the lesion was measured at baseline and then at 4, 8, and 12 weeks for each lesion. Physician and patient global assessment scores were recorded at week 12.
resultsIn minoxidil group, the baseline VASI score of 94 ± 9.68% reduced to 47.76 ± 17.25% at 12 weeks. In the placebo group, the VASI score reduced from 94 ± 9.68% to 67.93 ± 16.88%. Reduction in VASI was found to be greater in minoxidil group as compared with the placebo group ( P value = <0.001). The difference in the physician and patient's global assessment scores in both minoxidil and placebo groups was also statistically significant. LIMITATIONS: The study had a small sample size and a short follow-up period.
conclusionConcomitant use of phototherapy and minoxidil increases the rate of pigmentation with reduction in VASI score.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.